Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Lymphoma Clinical Trial

Official title:

A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00389506
• Other study ID #: 060240
• Secondary ID: 06-C-0240NCI-P67
• Status: Withdrawn
• Phase: N/A
• First received: October 18, 2006
• Last updated: March 14, 2012
• Start date: September 2006
• Est. completion date: May 2008

Study information

• Verified date: March 2012
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. LMB-2 immunotoxin can find cancer cells and kill them without harming normal cells. Giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin may kill more cancer cells.

PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin works in treating patients with Hodgkin's lymphoma.

Description:

OBJECTIVES:

Primary

• Determine the feasibility of pretreatment with fludarabine phosphate and cyclophosphamide in preventing neutralization of antibodies in patients with CD25-positive Hodgkin's lymphoma.

Secondary

• Determine the response rate in patients treated with LMB-2 immunotoxin.

• Determine the response duration in patients receiving this treatment.

• Correlate serum levels of LMB-2 immunotoxin with toxicity and response in these patients.

• Assess the development of neutralizing antibodies and the effect of these antibodies on blood levels of LMB-2 immunotoxin and toxicity.

• Correlate soluble Tac-peptide levels with treatment response in these patients.

OUTLINE: This is a nonrandomized, pilot study.

Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-4 and filgrastim (G-CSF) subcutaneously once daily beginning on day 5 and continuing until blood counts recover.

Beginning 4 weeks after completion of chemotherapy, patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.

Blood is obtained prior to and after chemotherapy and then periodically during LMB-2 immunotoxin therapy for pharmacokinetic studies to measure lymphocyte subsets.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histopathologically confirmed CD25+ Hodgkin's lymphoma

• At least 20% of the malignant cells positive by immunohistochemistry

• Stage II-IV disease

• Meets the following criteria:

• Failed standard chemotherapy

• Not eligible for curative salvage radiotherapy or chemotherapy

• Not eligible for or refused bone marrow transplantation

• Measurable disease

• No patient whose serum neutralizes LMB-2 immunotoxin in tissue culture, due either to antitoxin or antimouse-IgG antibodies

• No patient whose serum neutralizes > 75% of the activity of 1 µg/mL of LMB-2 immunotoxin

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Absolute neutrophil count = 1,000/mm³

• Platelet count = 50,000/mm³

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• ALT and AST = 2.5 times upper limit of normal

• Albumin = 3.0 g/dL

• Bilirubin = 2.2 mg/dL (< 5 mg/dL if Gilbert's syndrome is present)

• Creatinine = 1.4 mg/dL OR creatinine clearance = 50 mL/min

• No uncontrolled intercurrent illness including, but not limited to, any of the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Cardiac arrhythmia

• Psychiatric illness or social situations that would limit study compliance

• No HIV or hepatitis C positivity

• Hepatitis B surface antigen positivity allowed provided patient is receiving lamivudine

• LVEF = 45%

• DLCO = 50% of normal OR FEV_1 = 60% of normal

• No active second malignancy requiring treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No systemic cytotoxic chemotherapy within the past 4 weeks

• No systemic steroids (except stable doses of prednisone = 20 mg/day) within the past 4 weeks

• No monoclonal antibody therapy within the past 12 weeks

• No prior LMB-2 immunotoxin

• No concurrent warfarin

Study Design

Allocation: Non-Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma

Intervention

Biological:
• LMB-2 immunotoxin

Drug:
• cyclophosphamide

• fludarabine phosphate

Other:
• pharmacological study

Locations

Country	Name	City	State
United States	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Bethesda	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
National Institutes of Health Clinical Center (CC)	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of using fludarabine phosphate and cyclophosphamide to decrease neutralizing antibodies			No
Secondary	Response rate			No
Secondary	Response duration			No
Secondary	Correlation of serum levels of LMB-2 immunotoxin with toxicity and response			Yes
Secondary	Development of neutralizing antibodies and its effect on blood level of LMB-2 immunotoxin and toxicity			Yes
Secondary	Correlation of soluble Tac-peptide with treatment response			No